Cancer
Data update as of 31/12/2023
Area coordinator:
- Federico Rojo Todo
CV de Federico Rojo Todo (61.4 KB ) (3 pages)
FRojo@fjd.es
Research in the Cancer Area is carried out at three complementary levels: basic research, translational research and clinical research. The Cancer Area is made up of the Anatomic Pathology, Medical Oncology and Haematology groups, in addition to two associated groups.
Its objectives include:
- To deepen the knowledge of genetic and protein alterations in solid and haematological tumours.
- To further research the causes of resistance to current therapies, focusing on the study of the immune system and tumour support tissue, in order to open new immunotherapeutic treatment strategies.
- To advance treatment of the tumour microenvironment, both in drug development and clinical trials; to explore new technologies and approaches to better decipher the tumour microenvironment; and to discuss strategies to intervene in the pro-tumorigenic microenvironment and maximise therapeutic benefits.
- To research, in prospective samples, tumour cell and immune system markers that would allow for distinguishing patients who could benefit from next-generation therapies.
Scientific activity of the Cancer Area
|
2023 |
Anatomical Pathology |
Medical Oncology |
Haematology |
General, Thoracic, Neurosurgery and Other Surgery |
Radiation Oncology |
TOTAL |
|
|
PROJECTS |
→EU/NIH PROJECTS |
// |
2 |
1 |
// |
// |
3 |
|
→ISCIII PROJECTS |
6 |
6 |
2 |
// |
// |
14 |
|
|
→CYBER PROJECTS |
1 |
// |
// |
// |
// |
1 |
|
|
→MINISTERIAL PROJECTS |
// |
2 |
// |
// |
// |
2 |
|
|
→ACM PROJECTS |
1 |
1 |
1 |
// |
// |
3 |
|
|
→AWARDS |
// |
// |
// |
// |
// |
// |
|
|
→UNOFFICIAL PROJECTS |
17 |
28 |
22 |
// |
1 |
68 |
|
|
→OBSERVATIONAL STUDIES |
1 |
5 |
11 |
// |
// |
17 |
|
|
TOTAL |
26 |
44 |
37 |
// |
1 |
108 |
|
|
CLINICAL TRIALS |
→EARLY PHASES (I, I/II, II) |
1 |
257 |
72 |
// |
// |
330 |
|
→LATE PHASES (II/III, III, III/IV AND IV/OTHER) |
3 |
87 |
48 |
// |
2 |
140 |
|
|
TOTAL |
4 |
344 |
120 |
// |
2 |
470 |
Cancer Area Publications
|
2023 |
Total no. of publications |
No. of publications with IF |
Accumulated IF |
Average annual IF |
No. of journals in Q1 |
% of journals in Q1 |
No. of publications in Open Access |
No. of Clinical Practice Guidelines |
|
Anatomical Pathology |
73 |
68 |
418,5 |
6,15 |
34 |
50,00% |
41 |
3 |
|
Medical Oncology |
86 |
83 |
1260,8 |
15,19 |
54 |
65,06% |
66 |
11 |
|
Haematology |
73 |
69 |
524,4 |
7,60 |
35 |
50,72% |
59 |
9 |
|
General, Thoracic, Neurosurgery and Other Surgery |
12 |
8 |
61,1 |
7,64 |
1 |
12,50% |
8 |
1 |
|
Radiation Oncology |
6 |
4 |
14,4 |
3,60 |
1 |
25,00% |
5 |
2 |
|
CANCER AREA |
250 |
232 |
2279,2 |
9,82 |
125 |
53,88% |
179 |
26 |
List of the five most relevant publications in the Cancer Area during 2023
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C.
Lancet Oncol. 2023 Aug.24(8):913-924.
PMID: 37414060
FI: 51,1
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, Batistatou A, Burstein HJ, Carey LA, Cortes J, Denkert C, Diéras V, Jacot W, Koutras AK, Lebeau A, Loibl S, Modi S, Mosele MF, Provenzano E, Pruneri G, Reis-Filho JS, Rojo F, Salgado R, Schmid P, Schnitt SJ, Tolaney SM, Trapani D, Vincent-Salomon A, Wolff AC, Pentheroudakis G, André F, Curigliano G.
Ann Oncol. 2023 Jun 01.
PMID: 37269905
FI: 50,5
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.
Gonzalez Barca E, Tomás-Roca L, Esteve A, Rodriguez M, Gato L, Alonso-Alonso R, Martin Garcia-Sancho A, Cordoba R, Monter-Rovira A, Bastos-Oreiro M, Bergua Burgues JM, Sayas MJ, Viguria Alegria MC, Sanchez-Blanco JJ, Roig Pellicer M, Luzardo Henriquez HD, de Oña R, Cabezudo ME, Infante MS, Queizán Hernández JA, Sanz-Pamplona R, Blanco O, Mozos A, Climent F, Piris MA.
Am J Hematol. 2023 Jun.98(6):E134-E138.
PMID: 36882876
FI: 12,8
A complex microRNA regulatory network may control the HCP5/UTP3/c-Myc/VAMP3 signaling axis.
Cristóbal I, Santos A, Rojo F, García-Foncillas J.
Mol Ther. 2023 Apr 05.31(4):922-923.
PMID: 36933561
FI: 12,4
Long-Term Outcomes in Resected IDH-Mutant Subtypes of Diffuse Low-Grade Glioma.
Diez Valle R.
J Clin Oncol. 2023 Apr 10.41(11):1979-1981.
PMID: 36854064
FI: 45,4
Gender Perspective in the Cancer Area
The Cancer area is made up of a group of professionals committed to respect and equality among its team members, which seeks to promote the professional development of all its personnel without discrimination based on gender or age.
Future challenges
- Development of alternative research models (humanised mice, organoids) to recreate different human tumour models across a wide range of tumorigenesis stages.
- Development of new high-performance (massive sequencing, proteomics) and minimally invasive (liquid biopsy, imaging) diagnostic tools for cancer for patient selection and disease monitoring purposes.
Research groups
- Anatomical Pathology
- Medical Oncology
- Haematology
- General, Thoracic, Neurosurgery,and Other Surgery Associated Group
- Radiation Oncology Associated Group
